Yinhua Wang’s (16) and Guanghui Gao’s (17) studies suggested that camrelizumab plus vascular endothelial growth factor(VEGF) indicators significantly prolonged PFS and OS of advanced NSCLC patients. Here, VEGFA is linked to non-small cell lung carcinoma.